Navigation Links
Biotech Executive Salaries Continue to Rise Despite Weak Economy
Date:9/19/2012

ATLANTA, Sept. 19, 2012 /PRNewswire-USNewswire/ -- Amgen CEO Kevin Sharer, at $1.75 million in his final year before retirement, led the list of highest-salaried biotechnology executives in 2011, followed by John Martin, Gilead Sciences CEO, with $1.42 million, although Martin topped all executives in total compensation, with $54.58 million, to lead the "Millionaire's Club," according to data in the BioWorld Executive Compensation Report 2013: Trends in C-Level Salaries and Benefits in the Biopharma Market (ECR). 

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO)

Rounding out the top of the list of the highest-salaried U.S. biotech executives is George Scangos, Biogen Idec CEO, at $1.24 million, followed by Matthew Emmens, Vertex Pharmaceuticals, with $1.16 million.

It's still predominately a men's club, but women made noteworthy progress on some of the lists. Adelene Perkins, Infinity Pharmaceuticals CEO, at $820,000, came in at number 53 on the list of the top 167 CEOs, ranked by total annual compensation, to head a list of five female CEOs making the roll.

"In recent years, the biotech market has attained overall profitability, achieved its highest-ever market value and increased the number of annual product approvals; these are the executive decision-makers guiding the industry through the most profitable and productive period in its history, but also in what is, arguably, its most tenuous economic period," said Michael Harris, BioWorld's ECR senior editor.

Data on biotech corporate officers at companies outside the U.S. was included for the first time in ECR 2013 and the list shows only one executive, Peer Schatz, Qiagen CEO, at $1.31 million, earning more than $1 million.

"Negotiations for executive compensation packages can be better managed when there is comparative data on competitive-level positions," Harris said. "The compensation trends in BioWorld's ECR reveal that dynamics such as the recession, inherent volatility associated with drugmaking and the overwhelming risk of failure seem to have invoked the companies to double down on their efforts to rely on – and pay for – the best leadership."

Data in the 2013 ECR covers 798 C-level executives representing 258 companies in the U.S., with additional sections covering 87 executives representing 55 non-U.S. companies in Europe and Canada.

BioWorld is the biopharmaceutical industry's most respected news source for more than two decades. For a copy of the ECR, call (800) 477-6307 or, outside the U.S., (404) 262-5476 or visit www.bioworld.com.

CONTACT: Lynn Yoffee, Executive Editor, +1-404-262-5408

Web Site: http://www.bioworld.com


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Germany Prioritizes Medical Biotechnology with New Initiatives
5. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
6. Why Texas is #1 in Business: Local BioTech Company Expands
7. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
8. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
9. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
10. Biomass characterization technology research highlighted in Industrial Biotechnology journal
11. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):